Even Sun Pharmaceutical Industries Ltd., India's biggest drugmaker, is betting on increased use of branded generics in emerging markets. By 2021, it estimates such products will account for one-fifth of the $1.5 trillion a year spent on medicines worldwide. That's $300 billion -- or almost $100 billion ...
Read more: A $300-billion reason India's drug price cap will stay